



PATIENT GROUP

People with bowel cancer that has spread to other areas in the body, who now have no other treatment available to them.



REGISTRATION

CO.17 trial.



EGFR TESTING

Tumour sample sent for EGFR positive testing.



RANDOMISATION

Patients who are EGFR are randomised to one of two study groups.



GROUP A

Patients will receive best supportive care and study drug (Cetuximab) intravenously one day per week every week until their disease progresses or an unacceptable effect occurs. Best supportive care will continue as the usual treatment option.



GROUP B

Patients will receive best supportive care, which is the usual treatment option for these patients.



FOLLOW-UP

Regular patient check-up with doctor.